|
Market Closed -
Nasdaq
21:00:00 23/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 2.240 USD | -2.18% |
|
-8.20% | +4.67% |
| 09-08 | Veru Advances Oral Sabizabulin into Planned Phase 2 Clinical Trial for Daraxonrasib Resistant Metastatic Pancreatic Cancer | CI |
| 08-10 | Veru Inc., Q3 2026 Earnings Call, Aug 10, 2026 |
| Market Cap | 39.05M 34.86M 32.18M 29.2M 54.67M 3.71B 55.52M 387M 153M 1.94B 147M 143M 6.12B | P/E 2026 * |
-2.31x | P/E 2027 * | -2.24x |
|---|---|---|---|---|---|
| Enterprise Value | 39.05M 34.86M 32.18M 29.2M 54.67M 3.71B 55.52M 387M 153M 1.94B 147M 143M 6.12B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
89.63% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| VERU | Delayed | |
CBOE
| VERU | Real-time |
Last Transcript: Veru Inc.
| 1 day | -2.18% | ||
| 1 week | -8.20% | ||
| Current month | -15.79% | ||
| 1 month | -10.40% | ||
| 3 months | -0.88% | ||
| 6 months | -8.20% | ||
| Current year | +4.67% |
| 1 week | 2.22 |  | 2.41 |
| 1 month | 2.11 | | 2.75 |
| Current year | 2.05 | | 7.33 |
| 1 year | 2.05 | | 7.33 |
| 3 years | 2.05 | | 19.2 |
| 5 years | 2.05 | | 245.5 |
| 10 years | 2.05 | | 245.7 |
| Manager | Title | Age | Since |
|---|---|---|---|
Mitchell Steiner
CEO | Chief Executive Officer | 65 | 30/10/2016 |
Michele Greco
DFI | Director of Finance/CFO | 67 | 31/12/2012 |
| Chief Tech/Sci/R&D Officer | 64 | 31/03/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Mitchell Steiner
CHM | Chairman | 65 | 28/02/2018 |
Harry Fisch
BRD | Director/Board Member | 68 | 30/09/2016 |
| Director/Board Member | 68 | 28/02/2018 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 13/08/26 | Buy | Chief Technology Officer | 1,800 | 0.0112% | ||
| 04/05/26 | Free | Director | 160,000 | 0.9969% | ||
| 04/05/26 | Free | Director | 102,000 | 0.6355% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.18% | -8.20% | -45.63% | -72.31% | 39.22M | |
| +2.41% | -6.33% | +43.43% | +71.02% | 63.29B | |
| -0.15% | +3.11% | +10.29% | +72.56% | 54.89B | |
| +0.57% | +4.64% | +12.82% | +89.79% | 53.28B | |
| +0.37% | +3.07% | +28.23% | +51.53% | 45.81B | |
| -1.21% | +0.95% | +20.44% | +128.58% | 43.46B | |
| -0.37% | -1.20% | +252.94% | +568.54% | 40.23B | |
| +0.05% | +6.75% | +14.48% | +56.75% | 33.45B | |
| +1.19% | -5.84% | +27.86% | -0.65% | 23.7B | |
| -0.38% | +4.55% | +37.71% | +28.10% | 23.76B | |
| Average | +0.03% | -0.32% | +40.26% | +99.39% | 38.19B | |
| Weighted average by Cap. | +0.38% | +0.55% | +48.16% | +122.09% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -23.1M -20.62M -19.04M -17.28M -32.35M -2.19B -32.85M -229M -90.7M -1.15B -86.68M -84.84M -3.62B | -35.15M -31.38M -28.97M -26.29M -49.22M -3.34B -49.98M -349M -138M -1.75B -132M -129M -5.51B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/10/26 | US$2.240 | -2.18% | 122,566 |
| 22/10/26 | US$2.290 | -0.43% | 85,823 |
| 21/10/26 | US$2.300 | -3.36% | 99,813 |
| 20/10/26 | US$2.380 | +3.03% | 89,877 |
| 19/10/26 | US$2.310 | +0.43% | 88,138 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- VERU Stock
Select your edition
All financial news and data tailored to specific country editions
